Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs

Acumen Pharmaceuticals

Athira Pharma

Anavex Life Sciences

Biogen

BioVie Inc

Eli Lilly

Prothena

Cassava Sciences Inc

The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.

Trading Ideas On The Upcoming CTAD 2022 Conference

cobas 5800 is a new compact addition to the Roche molecular diagnostics portfolio that provides a scalable, high performance testing solution for labs of all sizes. Infectious diseases, such as HIV, Hepatitis, transplant associated viral illnesses, and respiratory and STIs, represent an ever-growing medical need for millions of patients worldwide.

Roche introduces the cobas 5800, a new molecular diagnostic system to expand access to PCR testing in the U.S.

Positive Topline Phase III Results Show Genentech's Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)

Basel, 26 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new OCREVUS® (ocrelizumab) data on disease progression and healthcare costs in patients with early-stage RRMS and long-term safety from all clinical trials in patients with relapsing MS (RMS) and primary progressive MS (PPMS). Data from the largest database of pregnancy outcomes for an anti-CD20 therapy in MS suggest consistent outcomes with epidemiological data in pregnant women and was an oral presentation today at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile

Early Treatment With Genentech's Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile

Basel, 24 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the cobas® SARS-CoV-2 Qualitative PCR test for use on the fully automated cobas® 6800 and cobas® 8800 Systems. This standalone test is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in nasal and nasopharyngeal samples from symptomatic patients who are suspected of having COVID-19 as determined by their healthcare provider.

Roche receives FDA clearance for COVID-19 PCR test for use on cobas 6800/8800 Systems

Basel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) will be presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 26-28 October 2022. These data include 35 abstracts, highlighting disease activity and progression results in early-stage RRMS, pregnancy outcomes from more than 2,000 women with MS and long-term safety data for OCREVUS, as well as global NMOSD data exploring impact of delayed treatment, clinical characterization of disease severity and stability, and accurate identification of people living with NMOSD through healthcare claims-based algorithms. Finally, the design of a Phase III study evaluating the efficacy and safety of satralizumab in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD), a rare, chronic and debilitating autoimmune disease primarily affecting the optic nerve, brain and spinal cord, will be presented.

Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022

Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022

Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.

Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales

A Roche executive said on Tuesday that positive trial data on an Alzheimer's disease drug candidate by rival Biogen was encouraging for companies such as Roche also pursing amyloid beta proteins as a drug target.

Roche exec says Biogen Alzheimer's data was reassuring

[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022

Basel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (“2.0”) for self-testing and professional use in countries accepting the CE Mark. Distribution of the new rapid test portfolio is projected to begin in the coming weeks.

Roche to introduce its next-generation portfolio of SARS-CoV-2 rapid antigen tests (“2.0”) under CE Mark for self-test and professional use

Basel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi® (risdiplam) in people with Type 1, 2 or 3 SMA aged 6 months to 60 years at time of enrolment. Patients had been previously treated with other approved or investigational SMA-targeting therapies, including nusinersen (Spinraza(R)) or onasemnogene abeparvovec (Zolgensma(R)). Data showed Evrysdi improved or maintained motor function and led to rapid increases in SMN protein levels which were sustained after 2-years of treatment. These data will be presented at the 27th World Muscle Society (WMS) congress, 11-15 October 2022.

Positive new data for Roche's Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)

Positive New Data for Genentech's Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)

Basel, 11 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of Anti-PRAME (EPR 20330) Rabbit Monoclonal Primary Antibody to identify PRAME protein expression in tissue samples from patients with suspected melanoma. Because the PRAME (PReferentially expressed Antigen in MElanoma) protein is expressed in most melanomas, the PRAME (EPR20330) Antibody* is used as an aid to differentiate between benign and malignant lesions to help improve diagnostic decisions. If PRAME expression is detected, this suggests that the lesion is malignant. “Every four minutes, one person dies from skin cancer. However, when detected early, localised melanoma is highly curable with a simple surgical excision,” said Thomas Schinecker, CEO of Roche Diagnostics. “Identifying this critical biomarker helps clinicians determine if their patient has melanoma. We're proud to add the PRAME assay to our already comprehensive test menu of dermatology biomarkers that help inform a patient's diagnosis and treatment.” Melanoma is an aggressive skin cancer that originates from melanocytes, which are cells in the skin and eyes that produce and contain melanin. Melanoma develops when unrepaired DNA damage to melanocytes triggers mutations that cause the melanocytes to grow rapidly and form malignant tumours. When detected early, the 5-year survival rate is 99 percent.1 The first test that is used to evaluate a potential melanocytic lesion is a hematoxylin and eosin (H&E) stain of the patient's tissue sample. However, not all melanomas are easily diagnosed using H&E alone. Studies suggest that detection of PRAME expression by immunohistochemistry (IHC) complements findings from routinely used tests and enables more informed clinical decisions and improved patient outcomes.2-4 In particularly challenging cases, use of PRAME IHC may highlight abnormal cells expressing the PRAME protein and provide more confidence in diagnosis of melanoma. More information about PRAME will be presented at the International Academy of Pathology 2022 World Congress in Sydney, Australia on 14 October 2022 in a session titled “The diagnostic approach to melanocytic lesions”. About the Anti-PRAME (EPR 20330) Rab bit Monoclonal Primary Antibody The PRAME (EPR20330) Antibody is fully automated on the full line of Roche BenchMark IHC/ISH instruments. This antibody is validated for use using OptiView DAB IHC Detection, ultraView Universal DAB Detection & ultraView Universal Alkaline Phosphatase Red Detection Kits giving added flexibility to laboratories and pathologists' preferences.

Roche launches PRAME (EPR20330) Antibody to identify PRAME protein expression in patients that may have melanoma

Basel, 05 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its industry-leading neuromuscular portfolio will be presented at the World Muscle Society (WMS) congress, 11th-15th October 2022. These data demonstrate Roche's commitment to advancing clinical understanding and supporting the development of treatments for people living with neuromuscular disorders.

Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022

Basel, 4 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU ® (fam-trastuzumab deruxtecan-nxki) may be considered as a targeted treatment. ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

Roche receives FDA approval for first companion diagnostic to identify patients with HER2 low metastatic breast cancer eligible for ENHERTU

Basel, 3 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Matt Sause (45), currently Head of Roche Diagnostics' North America Region, will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.

[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023

This can be attributed to Biogen's success with its Alzheimer's treatment - Lecanemab - in late-stage clinical trials.

What's Happening With Roche (RHHBY) Stock?

Novartis

NVS vs. RHHBY: Which Stock Is the Better Value Option?

NVS vs. RHHBY: Which Stock Should Value Investors Buy Now?

We comment on the latest company's development after its Pharma Day. Is Roche's dividend at risk? We don't believe so.

Roche: New Drugs Will Outpace Biosimilar Competition

The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.

Analysis: Alzheimer's drug breakthrough big boost for Roche, Eli Lilly

Basel, 26 September 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Julie Brown has notified the Board that she will step down as a member of the Roche Board of Directors as she has accepted a management role at another pharmaceutical company. This change will be effective from today.

Change in the Roche Board of Directors

Roche's new compact and modular system is designed to simplify daily operations, increase lab productivity, and support the delivery of better patient care through automation of manual tasks. cobas® pure integrated solutions brings together three diagnostic technologies on a single platform to optimize space and resources in low- to mid-volume laboratories.

News for Roche Holding AG Stock (RHHBY)